Equity

BGF World Healthscience Fund

Overview

Important Information: Capital at Risk. The value of investments and the income from them can fall as well as rise and are not guaranteed. Investors may not get back the amount originally invested.
Loading

Performance

Performance

Growth of Hypothetical 10,000

Performance chart data not available for display.
View full chart

Reinvestments

This fund does not have any distributions data as of now.
  From
30-Sep-2016
To
30-Sep-2017
From
30-Sep-2017
To
30-Sep-2018
From
30-Sep-2018
To
30-Sep-2019
From
30-Sep-2019
To
30-Sep-2020
From
30-Sep-2020
To
30-Sep-2021
Total Return (%)

as of Sep 30, 2021

12.87 18.42 0.39 20.35 14.79
  1Y 3Y 5Y 10y Incept.
14.79 11.52 13.14 15.30 9.44
  YTD 1m 3M 1Y 3Y 5Y 10y Incept.
7.77 -4.42 -1.00 14.79 38.70 85.38 315.19 534.00
The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted.

Key Facts

Key Facts

Size of Fund (Millions) as of Oct 22, 2021 USD 14,075.917
12m Trailing Yield -
Number of Holdings as of Sep 30, 2021 117
Base Currency U.S. Dollar
Fund Inception Date Apr 6, 2001
Share Class Inception Date Apr 6, 2001
Asset Class Equity
Morningstar Category Sector Equity Healthcare
SFDR Classification Other
Domicile Luxembourg
Regulatory Structure UCITS
Management Company BlackRock (Luxembourg) S.A.
Ongoing Charge 1.80%
ISIN LU0122379950
Bloomberg Ticker MEALU LX
Annual Management Fee 1.50%
Initial Charge 5.00%
Performance Fee 0.00%
SEDOL 7091148
Dealing Settlement Trade Date + 3 days
Dealing Frequency Daily, forward pricing basis
Minimum Initial Investment USD 5000
Minimum Subsequent Investment USD 1000
Use of Income Accumulating

Sustainability Characteristics

Sustainability Characteristics

Sustainability Characteristics can help investors integrate non-financial, sustainability considerations into their investment process. These metrics enable investors to evaluate funds based on their environmental, social, and governance (ESG) risks and opportunities. This analysis can provide insight into the effective management and long-term financial prospects of a fund.


The metrics below have been provided for transparency and informational purposes only. The existence of an ESG rating is not indicative of how or whether ESG factors will be integrated into a fund. The metrics are based on MSCI ESG Fund Ratings and, unless otherwise stated in fund documentation and included within a fund’s investment objective, do not change a fund’s investment objective or constrain the fund’s investable universe, and there is no indication that an ESG or Impact focused investment strategy or exclusionary screens will be adopted by a fund. For more information regarding a fund's investment strategy, please see the fund's prospectus.


Review the MSCI methodology behind Sustainability Characteristics, using links below.

MSCI ESG Fund Rating (AAA-CCC) as of Oct 7, 2021 BBB
MSCI ESG Quality Score (0-10) as of Oct 7, 2021 5.01
MSCI ESG Quality Score - Peer Percentile as of Oct 7, 2021 40.68
MSCI ESG % Coverage as of Oct 7, 2021 96.52
Fund Lipper Global Classification as of Oct 7, 2021 Equity Sector Healthcare
MSCI Weighted Average Carbon Intensity (Tons CO2E/$M SALES) as of Oct 7, 2021 19.21
Funds in Peer Group as of Oct 7, 2021 381
All data is from MSCI ESG Fund Ratings as of Oct 7, 2021, based on holdings as of Apr 30, 2021. As such, the fund’s sustainable characteristics may differ from MSCI ESG Fund Ratings from time to time.

To be included in MSCI ESG Fund Ratings, 65% of the fund’s gross weight must come from securities covered by MSCI ESG Research (certain cash positions and other asset types deemed not relevant for ESG analysis by MSCI are removed prior to calculating a fund’s gross weight; the absolute values of short positions are included but treated as uncovered), the fund’s holdings date must be less than one year old, and the fund must have at least ten securities. For newly launched funds, sustainability characteristics are typically available 6 months after launch.

Business Involvement

Business Involvement

Business Involvement metrics can help investors gain a more comprehensive view of specific activities in which a fund may be exposed through its investments.


Business Involvement metrics are not indicative of a fund’s investment objective, and, unless otherwise stated in fund documentation and included within a fund’s investment objective, do not change a fund’s investment objective or constrain the fund’s investable universe, and there is no indication that an ESG or Impact focused investment strategy or exclusionary screens will be adopted by a fund. For more information regarding a fund's investment strategy, please see the fund's prospectus.


Review the MSCI methodology behind the Business Involvement metrics, using links below.

MSCI - Controversial Weapons as of Sep 30, 2021 0.00%
MSCI - UN Global Compact Violators as of Sep 30, 2021 0.00%
MSCI - Nuclear Weapons as of Sep 30, 2021 0.00%
MSCI - Thermal Coal as of Sep 30, 2021 0.00%
MSCI - Civilian Firearms as of Sep 30, 2021 0.00%
MSCI - Oil Sands as of Sep 30, 2021 0.00%
MSCI - Tobacco as of Sep 30, 2021 0.00%

Business Involvement Coverage as of Sep 30, 2021 98.83%
Percentage of Fund not covered as of Sep 30, 2021 1.24%
BlackRock business involvement exposures as shown above for Thermal Coal and Oil Sands are calculated and reported for companies that generate more than 5% of revenue from thermal coal or oil sands as defined by MSCI ESG Research. For the exposure to companies that generate any revenue from thermal coal or oil sands (at a 0% revenue threshold), as defined by MSCI ESG Research, it is as follows: Thermal Coal 0.00% and for Oil Sands 0.00%.

Business Involvement metrics are calculated by BlackRock using data from MSCI ESG Research which provides a profile of each company’s specific business involvement. BlackRock leverages this data to provide a summed up view across holdings and translates it to a fund's market value exposure to the listed Business Involvement areas above.


Business Involvement metrics are designed only to identify companies where MSCI has conducted research and identified as having involvement in the covered activity. As a result, it is possible there is additional involvement in these covered activities where MSCI does not have coverage. This information should not be used to produce comprehensive lists of companies without involvement. Business Involvement metrics are only displayed if at least 1% of the fund’s gross weight includes securities covered by MSCI ESG Research.

ESG Integration

ESG Integration

ESG integration is the practice of incorporating material environmental, social and governance (ESG) information or insights alongside traditional measures into the investment decision process to improve long term financial outcomes of portfolios. Unless otherwise stated in Fund documentation or included within the Fund’s investment objective, inclusion of this statement does not imply that the Fund has an ESG-aligned investment objective, but rather describes how ESG information is considered as part of the overall investment process.


The Fund manager includes ESG considerations in combination with other information in the research and decision phases of the investment process. The Fund manager conducts regular portfolio reviews between with the Risk and Quantitative Analysis group and with the Chief Investment Officers. These reviews include discussion of the portfolio’s exposure to material ESG risks, as well as exposure to sustainability-related business involvements, climate-related metrics, and other factors.

Ratings

Ratings

Morningstar Rating

4 stars
Overall Morningstar Rating for BGF World Healthscience Fund, Class A2, as of Sep 30, 2021 rated against 383 Sector Equity Healthcare Funds.

Risk Indicator

Risk Indicator

1
2
3
4
5
6
7
Low Risk High Risk
Low Yield High Yield

Holdings

Holdings

as of Sep 30, 2021
Name Weight (%)
PFIZER INC 5.35
ABBOTT LABORATORIES 5.34
THERMO FISHER SCIENTIFIC INC 5.22
UNITEDHEALTH GROUP INC 5.17
JOHNSON & JOHNSON 4.74
Name Weight (%)
ROCHE HOLDING PAR AG 3.68
SANOFI SA 3.08
ASTRAZENECA PLC 2.99
BOSTON SCIENTIFIC CORP 2.58
MEDTRONIC PLC 2.56
Holdings subject to change

Pricing & Exchange

Investor Class Currency Distribution Frequency NAV NAV Amount Change NAV % Change 52wk High 52wk Low Bid Price ISIN Offer Price TIS
A2 USD Accumulating 64.49 0.49 0.77 66.68 52.51 - LU0122379950 - -
I2 USD - 14.74 0.11 0.75 15.22 11.89 - LU1960219225 - -
A2 Hgd JPY Accumulating 1,388.00 11.00 0.80 1,436.00 1,136.00 - LU1948809360 - -
D2 USD Accumulating 71.67 0.55 0.77 74.04 57.93 - LU0329593007 - -
A2 Hgd HKD Accumulating 221.84 1.69 0.77 229.48 180.82 - LU1061106388 - -
A2 EUR Accumulating 55.38 0.42 0.76 56.83 44.95 - LU0171307068 - -
A2 Hgd AUD Accumulating 21.70 0.16 0.74 22.48 17.74 - LU1023059063 - -
E2 EUR Accumulating 50.04 0.38 0.77 51.39 40.81 - LU0171309270 - -
D4 USD Annual 16.34 0.12 0.74 16.88 13.21 - LU1728553774 - -
A2 Hgd EUR Accumulating 14.72 0.11 0.75 15.24 12.09 - LU1822774284 - -
D2 EUR Accumulating 61.54 0.46 0.75 63.07 49.59 - LU0827889485 - -
C2 EUR Accumulating 43.20 0.32 0.75 44.44 35.50 - LU0331289677 - -
C2 USD Accumulating 50.31 0.38 0.76 52.11 41.47 - LU0147404148 - -
X2 USD Accumulating 79.60 0.61 0.77 82.13 63.72 - LU0462856898 - -
Class AI2 EUR - 14.74 0.11 0.75 15.13 11.96 - LU1960224654 - -
I2 EUR - 12.66 0.10 0.80 12.97 10.17 - LU1960219571 - -
A2 Hgd SGD Accumulating 22.00 0.17 0.78 22.76 17.92 - LU1057294990 - -
E2 USD Accumulating 58.27 0.44 0.76 60.29 47.68 - LU0122380701 - -
A2 Hgd CNH Accumulating 188.00 1.45 0.78 193.64 149.75 - LU1254117382 - -

Portfolio Managers

Portfolio Managers

Erin Xie
Head of Health Sciences Investing, Active Equities

Erin Xie, PhD, Managing Director and portfolio manager, is the head of the Health Sciences team, part of BlackRock's Active Equity Group.

Jeff Lee
Jeff Lee
Xiang Liu
Xiang Liu

Literature

Literature